Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene

Molecular Pharmacology

Volumn 67, Issue 6, 2005, Pages 1920-1934

  Wallace, Derek A ^a   Johnston, Lee Ann ^a,d   Huston, Elaine ^a   MacMaster, Douglas ^a,e   Houslay, Thomas M ^a   Cheung, York Fong ^a   Campbell, Lachlan ^a,b   Millen, Jenni E ^a,f   Smith, Robin A ^b   Gall, Irene ^a   Knowles, Richard G ^b   Sullivan, Michael ^c   Houslay, Miles D ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d Randox Laboratories Ltd   (United Kingdom)

^e DuPont Teijin Films   (United Kingdom)

^f EvoQuest Custom Services   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CILOMILAST; CYCLIC AMP PHOSPHODIESTERASE; DENBUFYLLINE; PROTEINASE INHIBITOR; ROFLUMILAST; ROLIPRAM; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ISOENZYME; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BAT; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SWINE; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; CELL STRAIN COS1; CERCOPITHECUS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; INTRACELLULAR FLUID; METABOLISM; MOLECULAR GENETICS; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTRACELLULAR FLUID; ISOENZYMES; MICE; MOLECULAR SEQUENCE DATA; PHOSPHODIESTERASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 21744438149     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.009423     Document Type: Article

References (40)

1. Alfonso-Jaume MA, Mahimkar R, and Lovett DH (2004) Co-operative interactions between NFAT (nuclear factor of activated T cells) c1 and the zinc finger transcription factors Sp1/Sp3 and Egr-1 regulate MT1-MMP (membrane type 1 matrix metalloproteinase) transcription by glomerular mesangial cells. Biochem J 380:735-747.
2. 2+-triggered membrane association with selectivity for interaction with phosphatidic acid. J Biol Chem 277:28298-28309.
3. Baillie GS, MacKenzie SJ, McPhee I, and Houslay MD (2000) Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol 131:811-819.
4. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, and Houslay MD (2003) beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci USA 100:940-945.
5. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, and Heeke GV (2004) Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD and nonsmokers. Am J Physiol 287:L332-L343.
6. Beard MB, Huston E, Campbell L, Gall I, McPhee I, Yarwood S, Scotland G, and Houslay MD (2002) In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting. Cell Signal 14:453-465.
7. Beavo JA and Brunton LL (2002) Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 3:710-718.
8. Bolger G, Michaeli T, Martins T, St. John T, Steiner B, Rodgers L, Riggs M, Wigler M, and Ferguson K (1993) A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13:6558-6571.
9. Bolger GB (1994) Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal 6:851-859.
10. Bolger GB, McCahill A, Huston E, Cheung YF, McSorley T, Baillie GS, and Houslay MD (2003) The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with β-arrestins. J Biol Chem 278:49230-49238.
11. Burnouf C and Pruniaux MP (2002) Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 8:1255-1296.
12. Chapman CG, Meadows HJ, Godden RJ, Campbell DA, Duckworth M, Kelsell RE, Murdock PR, Randall AD, Rennie GI, and Gloger IS (2000) Cloning, localisation and functional expression of a novel human, cerebellum specific, two pore domain potassium channel. Brain Res Mol Brain Res 82:74-83.
13. Conti M, Richter W, Mehats C, Livera G, Park JY, and Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496.
14. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, et al. (2003) Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168:976-982.
15. Giembycz MA (2002) Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 57:48-64.
16. Hoffmann R, Wilkinson IR, McCallum JF, Engels P, and Houslay MD (1998) cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem J 333:139-149.
17. Houslay MD (2001) PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69:249-315.
18. Houslay MD and Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18.
19. Huston E, Beard M, McCallum F, Pyne NJ, Vandenabeele P, Scotland G, and Houslay MD (2000) The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3. Consequences for altered intracellular distribution. J Biol Chem 275:28063-28074.
20. Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G, and Houslay MD (1996) The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. J Biol Chem 271:31334-31344.
21. Johnston LA, Erdogan S, Cheung YF, Sullivan M, Barber R, Lynch MJ, Baillie GS, Van Heeke G, Adams DR, Huston E, et al. (2004) Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. Biochem J 380:371-384.
22. Le Jeune IR, Shepherd M, Van Heeke G, Houslay MD, and Hall IP (2002) Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells: identification and characterization of a novel PDE4D5 Promoter. J Biol Chem 277:35980-35989.
23. MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, and Houslay MD (2000) ERK2 MAP kinase binding, phosphorylation and regulation of PDE4D cAMP specific phosphodiesterases: the involvement of C-terminal docking sites and N-terminal UCR regions. J Biol Chem 275:16609-16617.
24. MacKenzie SJ, Baillie GS, McPhee I, MacKenzie C, Seamons R, McSorley T, Millen J, Beard MB, van Heeke G, and Houslay MD (2002) Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in upstream conserved region 1 (UCR1). Br J Pharmacol 136:421-433.
25. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, and Jimmo SL (2003) Cyclic nucleotide phosphodiesterase activity, expression and targeting in cells of the cardiovascular system. Mol Pharmacol 64:533-546.
26. McPhee I, Yarwood SJ, Huston E, Scotland G, Beard MB, Ross AH, Houslay ES, and Houslay MD (1999) Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B: consequences for rolipram inhibition. J Biol Chem 274:11796-11810.
27. Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, and Conti M (2003) PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J 17:1831-1841.
28. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, et al. (2004) Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95:67-75.
29. Oki N, Takahashi SI, Hidaka H, and Conti M (2000) Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role Of pde4d3 phosphodiesterase activation. J Biol Chem 275:10831-10837.
30. 2 and Sp3, are mediated by CACCC element and Sp1 sites of human monoamine oxidase (MAO) B gene. J Biol Chem 279:21021-21028.
31. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, Miller WE, McLean AJ, Conti M, Houslay MD, et al. (2002) Targeting of cyclic AMP degradation to β2-adrenergic receptors by β-arrestins. Science (Wash DC) 298:834-836.
32. Perry SJ and Lefkowitz RJ (2002) Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 12:130-138.
33. Rena G, Begg F, Ross A, MacKenzie C, McPhee I, Campbell L, Huston E, Sullivan M, and Houslay MD (2001) Molecular cloning and characterization of the novel cAMP specific phosphodiesterase, PDE4A10. Mol Pharmacol 59:996-1011.
34. Sette C and Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem 271:16526-16534.
35. Shepherd MC, Baillie GS, Stirling DI, and Houslay MD (2004) Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol 142:339-351.
36. Spina D (2003) Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63:2575-2594.
37. Sullivan M, Rena G, Begg F, Gordon L, Olsen AS, and Houslay MD (1998) Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. Biochem J 333:693-703.
38. Terry R, Cheung YF, Praestegaard M, Baillie GS, Huston E, Gall I, Adams DR, and Houslay MD (2003) Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. Cell Signal 15:955-971.
39. Timmer W, Leclerc V, Birraux G, Neuhauser M, Hatzelmann A, Bethke T, and Wurst W (2002) The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 42:297-303.
40. Vicini E and Conti M (1997) Characterization of an intronic promoter of a cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol Endocrinol 11:839-850.